The user is seeking oral Minoxidil in Europe due to issues with topical Minoxidil causing dandruff and dry scalp. They have started using oral Finasteride and are considering Ketoconazole shampoo.
Topical finasteride may reduce more scalp DHT but is seen as inconsistent and messy compared to oral finasteride. Users report mixed results with both forms, with some preferring oral for its convenience and consistent dosing, while others find topical effective but harder to apply.
The user has been using 1.25 mg of oral minoxidil and finasteride since September 2025 to address diffuse hair thinning, and is considering trying a new shampoo. Other users suggest increasing the minoxidil dose and trying dutasteride.
PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.
Clascoterone is suggested as an alternative for those who experience side effects from finasteride and dutasteride. It is not widely available yet, but some users are obtaining it from compounding pharmacies or suppliers like Echemi.
The conversation discusses the storage and use of pyrilutamide for hair loss, where one user advises against keeping it in the freezer as it may crystallize the active compounds.
The conversation discusses the need for a localized 5-alpha reductase inhibitor that only affects the scalp without systemic side effects, similar to pyrilutamide's approach. Current treatments like topical liposomal finasteride and dutasteride are mentioned, but concerns about their systemic effects and lack of research are highlighted.
The post discusses using ketoconazole and finasteride for hair loss, suggesting waiting to use minoxidil. The user also mentions microneedling and emphasizes confidence over hair appearance.
The reasoning for GSK's approval of dutasteride for hair loss in Japan and South Korea but not the US, with alternatives such as finasteride, minoxidil and RU58841 mentioned.